ExploreWatchlistsPricing
  1. JP-listed companies
  2. Astellas Pharma Inc.
  3. Financials
  4. Total cash & short-term investments

Astellas Pharma Inc. (4503)

Market cap
¥4.62T
P/E ratio
18.3x
Astellas Pharma develops, manufactures, and sells pharmaceutical products globally through a network of 77 subsidiaries across the US, Europe, and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal cash & short-term investments (Million JPY)YoY (%)
Mar 31, 2025218,313-40.10%
Mar 31, 2024364,471-8.11%
Mar 31, 2023396,624+17.59%
Mar 31, 2022337,283+1.69%
Mar 31, 2021331,688+1.17%
Mar 31, 2020327,850+4.52%
Mar 31, 2019313,681+229.62%
Mar 31, 201895,165-9.19%
Mar 31, 2017104,791+45.44%
Mar 31, 201672,051-31.08%
Mar 31, 2015104,542

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat